80106 Federal Register / Vol. 85, No. 239 / Friday, December 11, 2020 / Notices 

successful implementation and 

evaluation of surveillance and 

prevention activities. The OD2A TA 

Center is designed to enhance the 

efficiency, coordination, and 

effectiveness of TA efforts by 

streamlining and centralizing the 

provision of overdose surveillance and 

prevention TA. TA to OD2A recipients 

is divided into four different levels with 

multiple modes of TA delivery and 

involves a wide range of TA providers 

including CDC staff, internal and 

external subject matter experts (SMEs) 

and program partners as well as ICF 

staff. 

The evaluation consists of two webbased surveys designed to collect 

process and outcome measures about 

TA access, utilization, and outcomes 

across all 66 OD2A recipient programs. 

The Technical Assistance Feedback 

Form will be administered to collect 

immediate feedback following 

individual TA encounters and group 

events such as webinars and in-person 

trainings. The Annual OD2A TA Survey 

will be distributed twice (mid-point and 

final) to assess satisfaction with overall 

TA provided and the extent to which 

TA supports informed implementation 

of OD2A strategies. The information 

obtained through this evaluation will 

allow TA providers to assess OD2A 

recipients’ experience and utility of 

knowledge and resources gained 

through individual TA support, peer-topeer sessions, and other group trainings. 

Ultimately, the evaluation data will 

inform subsequent rounds of TA and 

allow TA providers to make necessary 

adjustments to the overall TA strategy 

for continuous quality improvement. 

This will ensure recipients have the 

support necessary to implement 

strategies that will improve opioid 

surveillance and prevention policies 

and practices within their communities. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

OD2A Recipients .............................. TA Feedback Form .......................... 671 2 5/60 112 

Annual OD2A TA Survey .................. ........................................................... 440 1 15/60 110 

Total ........................................... ........................................................... ........................ ........................ ........................ 222 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2020–27325 Filed 12–10–20; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–21–20OT] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled ‘‘Mycoplasma 

genitalium Treatment Failure Registry’’ 

to the Office of Management and Budget 

(OMB) for review and approval. CDC 

previously published a ‘‘Proposed Data 

Collection Submitted for Public 

Comment and Recommendations’’ 

notice on June 5, 2020 to obtain 

comments from the public and affected 

agencies. CDC did not receive comments 

related to the previous notice. This 

notice serves to allow an additional 30 

days for public and affected agency 

comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

Mycoplasma genitalium Treatment 

Failure Registry—New—National Center 

for HIV/AIDS, Viral Hepatitis, STD, and 

TB Prevention (NCHHSTP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

The Centers for Disease Control and 

Prevention (CDC), Division of STD 

Prevention requests a three-year 

approval of an information collection 

request for the Mycoplasma genitalium 

Treatment Failure Registry, which will 

entail use of a standardized Case Report 

Form. 

The primary goal of this activity is to 

establish a registry to monitor cases of 

Mycoplasma genitalium (M. genitalium) 

treatment failure in the United States. 

The project objectives are as follows: (1) 

Using existing clinical data, describe 

demographic and behavioral factors 

among patients with documented 

Mycoplasma genitalium who fail 

current CDC-recommended treatment, 

(2) Using existing clinical data, describe 

antibiotic regimens utilized among 

patients with Mycoplasma genitalium 

treatment failure, including 

documentation of clinical and 


jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 85, No. 239 / Friday, December 11, 2020 / Notices 80107 

microbiologic cure, (3) Using existing 

laboratory specimens, monitor genetic 

mutations associated with macrolide or 

fluroquinolone antibiotic resistance. 

Data captured on the standardized 

Case Report Form will be analyzed to 

determine outcomes from usage of 

second-line antibiotic therapy for 

M.gentialium. These data may inform 

future CDC STD Treatment Guidelines. 

There are an estimated 100 respondents 

(anticipated to report once per year) 

who will be clinicians in private and 

public health care settings. The data 

collection is necessary as there are no 

current national recommendations for 

patients who fail current CDCrecommended therapy for M. 

genitalium. Each case report form is 

anticipated to take up to 60 minutes to 

complete. This data collection provides 

CDC with information to determine 

which second-line treatments are most 

clinically effective, as well as 

determining antibiotic resistance 

patterns of M. genitalium throughout the 

US. There are no costs to respondents 

other than their time. The estimated 

annualized burden hours for this data 

collection are 100 hours. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name No. of Respondents 

No. responses 

per respondent 

Average burden per response 

(in hours) 

Physician or Nurse Practitioner.M. genitalium Treatment Failure Registry Case Report Form 100 1 1 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2020–27326 Filed 12–10–20; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, Disability, 

and Injury Prevention and Control Special 

Emphasis Panel (SEP)-DP21–002, 

Epidemiologic Cohort Study of Interstitial 

Cystitis. 

Date: March 30, 2021. 

Time: 10:00 a.m.–6:00 p.m., EST. 

Place: Teleconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: Jaya 

Raman Ph.D., Scientific Review Officer, CDC, 

4770 Buford Highway, Mailstop F80, Atlanta, 

Georgia 30341, Telephone: (770) 488–6511, 

JRaman@cdc.gov. 

The Director, Strategic Business Initiatives 

Unit, Office of the Chief Operating Officer, 

Centers for Disease Control and Prevention, 

has been delegated the authority to sign 

Federal Register notices pertaining to 

announcements of meetings and other 

committee management activities, for both 

the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives 

Unit,Office of the Chief Operating 

Officer,Centers for Disease Control and 

Prevention. 

[FR Doc. 2020–27229 Filed 12–10–20; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Centers for Disease Control and 

Prevention (CDC)/Health Resources 

and Services Administration (HRSA) 

Advisory Committee on HIV, Viral 

Hepatitis and STD Prevention and 

Treatment (CHACHSPT); Notice of 

Charter Renewal 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of charter renewal. 

SUMMARY: This gives notice under the 

Federal Advisory Committee Act of 

October 6, 1972, that the Centers for 

Disease Control and Prevention (CDC)/ 

Health Resources and Services 

Administration (HRSA) Advisory 

Committee on HIV, Viral Hepatitis and 

STD Prevention and Treatment 

(CHACHSPT), Centers for Disease 

Control and Prevention, Department of 

Health and Human Services, has been 

renewed for a 2-year period through 

November 25, 2022. 

FOR FURTHER INFORMATION CONTACT: 

Jonathan Mermin, MD, MPH, 

Designated Federal Officer, Centers for 

Disease Control and Prevention (CDC)/ 

Health Resources and Services 

Administration (HRSA) Advisory 

Committee on HIV, Viral Hepatitis and 

STD Prevention and Treatment 

(CHACHSPT), CDC, HHS, 1600 Clifton 

Road NE, Mailstop US8–6, Atlanta, 

Georgia 30329–4027; Telephone (404) 

639–8000, JMermin@cdc.gov. 

SUPPLEMENTARY INFORMATION: The 

Director, Strategic Business Initiatives 

Unit, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention, has been delegated the 

authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2020–27227 Filed 12–10–20; 8:45 am] 

BILLING CODE 4163–18–P 


jbell on DSKJLSW7X2PROD with NOTICES